Skip to main content
Caplight Logo









Neuvasq Biotechnologies

Neuvasq Biotechnologies

Private
BelgiumHealthcare & Life Scienceshttps://neuvasq.com/

Last Round

Series A

Jun 22, 2021

Total Funding Raised

$23.8M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Neuvasq Biotechnologies is a biotechnology company that develops multispecific antibody-based therapies to restore and protect the integrity of the blood-brain and blood-retina barriers for the treatment of neurological and ophthalmic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

multispecific antibodyneurovascular barrierblood-brain barrierblood-retina barrierbiotech startupWnt signalingophthalmic therapyneurological disorderbispecific antibodytrispecific moleculedrug discoverypreclinical biotechvascular retinopathybiologicstherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neuvasq Biotechnologies Comparables

Compare Neuvasq Biotechnologies with similar companies based on industry and business-model similarity.

Neuvasq Biotechnologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Merck & Co., Inc.
79%
Lys Therapeutics
78%
Surrozen
74%

Neuvasq Biotechnologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 22, 2021

Neuvasq Biotechnologies Investors

Notable investors and investment history

Neuvasq Biotechnologies investors
InvestorRounds
Federal Holding and Investment CompanySeries A
Newton BiocapitalSeries A
Wallonie EntreprendreSeries A
ORSASeries A
SambrinvestSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors grew 79% MoM.

  • Apr 16, 2026

    Monthly visitors increased 2700% MoM.

Neuvasq Biotechnologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Neuvasq Biotechnologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Neuvasq Biotechnologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersBelgium
Employee Range15
Year Founded2021
Last FundingJun 22, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?